Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Healthy
Interventions: SKL24741, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Acute Pain
Interventions: XG005 tablet, Placebo tablet; Drug
Lead sponsor: Xgene Pharmaceutical Group; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Hialeah, Florida + 5 more

Conditions: Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Contraceptive Usage
Interventions: COntraceptive pathway; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Psoriasis
Interventions: Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more

Conditions: COVID-19, Post Acute Sequelae of SARS-CoV-2
Interventions: Muse S™ Headband system; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine; Drug
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Healthy Volunteers
Interventions: Salt tablet; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Ischemia
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cerebral Palsy
Interventions: HMB + Vitamin D3; Dietary Supplement
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 13 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Breast Cancer
Interventions: App-based Mindfulness Training; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Migraine
Interventions: Atogepant, Placebo for Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 32
States / cities: Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more

Conditions: Hepatitis C
Interventions: SOF, VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 50
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 38 more

Conditions: Unverricht-Lundborg Disease
Interventions: Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • New York, New York + 1 more

Conditions: Hepatitis C Virus, HIV
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more

Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions: alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: Healthy
Interventions: HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 81
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more

Conditions: Cystic Fibrosis
Interventions: TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 30
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: delafloxacin, vancomycin, aztreonam; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more

Conditions: Gynecologic Cancer, Colorectal Cancer, Lung Cancer
Interventions: I Can PIC, Historical control survey, Post-intervention survey (I Can PIC participants), Follow-Up survey (I Can PIC participants); Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Impotence
Interventions: tadalafil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more

Search by objective public record fields.

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Contraceptive Pathway and Contraception Continuation Rates

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Mindfulness Intervention for Post-Covid Symptoms

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

Evaluation of Salt Sensitivity in Young Adults

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

HMB Cerebral Palsy Pilot Study

A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity

To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C